1:30pm Development and functional characterization of ELN28, a Novel soloMER Drug Conjugate (SDC) targeting TNFα and JAK enzymes in Immune Mediated Inflammatory Diseases
Time: 1:30 pm
day: Day Two Preclinical & Clinical Development Track
Details:
- Elasmogen has designed a first-in-class soloMER drug conjugate tailor-made for autoimmune and inflammatory diseases.
- This innovative treatment utilizes a super-potent, novel-acting multivalent anti-TNFα soloMER to site-deliver an anti-inflammatory JAK inhibitor payload, Tofacitinib.
- We will be presenting in vivo, ex vivo efficacy, PK and Biodistribution data.
